CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM...Show all
Company (Alive / Active)
Phone: 617-278-6655
47 Thrndike Street
Suite B1-1
Cambridge, 02141
Massachusetts, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Decimmune Therapeutics | $10.5M | Oct 3, 2014 |
| See all 17 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Humanized, anti-n2 antibodies | Mar 12, 2014 | Aug 09, 2016 | Patent |
| Humanized, anti-n2 antibodies | Mar 12, 2014 | Jan 26, 2016 | Patent |
| Anti-inflammatory antibodies and uses therefor | Nov 05, 2012 | Jun 30, 2015 | Patent |
| Anti-inflammatory antibodies and uses therefor | Dec 07, 2010 | Dec 04, 2012 | Patent |
| Humanized, anti-n2 antibodies | Jun 29, 2016 | Application |
